Hjem › Epitelcellekarcinom i eggstokkene › Tennessee
Kliniske studier for Epitelcellekarcinom i eggstokkene i Tennessee
6 studier for Epitelcellekarcinom i eggstokkene søker deltakere på steder i Tennessee.
Byer i Tennessee
Offisiell studietekst (engelsk)
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
- Erlanger Health, Chattanooga
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 5. okt. 2026 · NCT06915025Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer
- University of Tennessee Medical Center - Knoxville, Knoxville
RekruttererObservasjonsstudie
Alder 18 og eldre · Kvinner · Oppdatert 17. aug. 2026 · NCT07764133AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- Research Site, Germantown
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 21. jul. 2026 · NCT07218809Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
- Sarah Cannon Research Institute (Oncology Associates of Oregon PC), Nashville
RekruttererFase 3
Alder 18 og eldre · Kvinner · Oppdatert 2. jul. 2026 · NCT06819007CT-95 in Advanced Cancers Associated With Mesothelin Expression
- Context Investigational Site, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 12. jun. 2026 · NCT06756035Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- Vanderbilt University Medical Center, Nashville
RekruttererFase 1
Alder 18 og eldre · Alle kjønn · Oppdatert 15. aug. 2025 · NCT04429542Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.